Impact of a Gastrointestinal Stable Probiotic Supplement <i>Bacillus coagulans</i> LBSC on Human Gut Microbiome Modulation

Maity, Chiranjit; Gupta, Anil Kumar; Saroj, Dina B; Biyani, Atul; Bagkar, Pratik; Kulkarni, Jayshree; Dixit, Yogini

doi:10.1080/19390211.2020.1814931

Cited by 30 publications

(32 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microbial dysbiosis , that is, imbalance in gastrointestinal microbiome is a known cause for prognosis of such gastrointestinal conditions. [ 24 ] Bacteriotherapy with probiotics helps in reprogramming the microbial balance of gut and restore healthy and complex host-microbiota interactions. [ 41 ] Clinical efficacies of probiotics are strain dependent and therapeutic effectiveness depends on specific clinical circumstances like digestive and nondigestive disorders.…”

Section: Discussionmentioning

confidence: 99%

“…B coagulans LBSC [DSM17654; GenBank: CP022701.1 & GenBank: ATW84696.1 ( gyrB )] is previously reported as a genomically safe probiotic microorganism, [ 35 ] efficacious for treating acute diarrhea and abdominal discomforts [ 26 ] and can modulate gut microbiome in human subjects. [ 24 ]…”

Section: Discussionmentioning

confidence: 99%

“…Strains of B coagulans are spore-former and widely studied probiotic for production of antimicrobials like coagulin and lactosporin, immune-modulation and modulation of gut microbiome. [ 24 ] The naturally encapsulated coating around the cell protects it from various drought conditions like high temperature, desiccation, osmolarity, etc. This highly resilient allochthonous probiotic can survive and proliferate in gastric acid, pepsin, pancreatin, ions, digestive enzymes, bile, and mucin of gastrointestine.…”

Section: Introductionmentioning

confidence: 99%

“…The therapeutic activity of B coagulans is well established for various ailments like diarrhea, antibiotic-associated diarrhea, hypercholesterolemia, immune modulation, IBS, IBD, Clostridium difficile -induced colitis, dysbiosis , Helicobacter pylori infection, gingivitis, necrotizing enterocolitis, and other FGID's. [ 23 , 24 , 26 , 27 ] Some strains of B coagulans have shown clinical efficacy by significantly improving the bowel pattern, diarrheal duration and frequency, abdominal pain, and bloating associated with IBS through randomized control trials (RCTs) studies. [ 28 – 34 ] However, few of these clinical studies have also reported about variable effect of B coagulans strains for IBS symptoms instead of complete relive of symptoms subset.…”

Section: Introductionmentioning

confidence: 99%

“…This probiotic strain has been previously reported for its genomic safety [ 35 ] and clinical efficacy. [ 24 , 26 ] The frequency and severity of gastrointestinal symptoms, stool consistency, and QoL in the intervened (test) and control (placebo) group were assessed as outcome variables.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome

Gupta¹,

Maity²

2021

Medicine

Self Cite

View full text Add to dashboard Cite

Goals: To evaluate safety and efficacy of Bacillus coagulans LBSC [DSM17654] in irritable bowel syndrome (IBS) through a prospective, interventional, randomized, double-blind, and placebo-controlled, CONSORT compliant clinical trial. Background: Bacteriotherapy shows promising impact on alleviating clinical conditions of IBS and associated functional gastrointestinal disorders. B coagulans LBSC is a genetically and phenotypically safe probiotic strain used in this study to study its impact on ameliorating IBS symptoms and improving quality of life. Methods: In this interventional, randomized, double-blind, placebo-controlled clinical study, total 40 subjects (18–65 years) were screened through Rome IV criteria and randomized into 2 groups, that is, interventional and placebo arm (n = 20/arm). Similar dosages were received by both the arm, that is, placebo (vehicle) and interventional arm (B coagulans LBSC, 6 billion/d) for a period of 80 days. Study completed with per protocol subjects (n = 38) and results were considered to evaluate the primary and secondary endpoints. Results: Assessment through Digestive Symptom Frequency Questionnaire 5 point Likert scale showed significant improvement in interventional arm compared to placebo on symptoms such as bloating/cramping, abdominal pain, diarrhea, constipation, stomach rumbling, nausea, vomiting, headache, and anxiety. Maximum of “no symptoms” cases and mild to moderate gastrointestinal symptoms along with improved stool consistency were from interventional arm tested following IBS severity scoring system and Bristol stool form scale. Upper gastrointestinal endoscopy revealed no clinical difference of gastrointestinal mucosa between both the arms. B coagulans LBSC was well tolerated with no serious adverse events. Conclusions: B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome

Gupta¹,

Maity²

2021

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Encapsulation techniques, action mechanisms, and evaluation models of probiotics: Recent advances and future prospects

Yang,

Wei,

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

The related studies of probiotics‐based functional foods have recently attracted increasing interests in developing new types of oral administration systems. Probiotics has various biological functions, including increasing adsorption ability of nutrients, competitively rejecting pathogenic organisms, and regulating the immune system. It is well known that probiotics cannot be worked until their colonies reach the intestine alive, as well as the amount reaches 106–107 colony‐forming units/g at the end of product's shelf life. However, the delivery of probiotics to the colon through oral administration is always challenging due to weak viability under exposure to harsh conditions in the presence of ions and small molecules from the upper gastrointestinal tract. Moreover, the low viability of the probiotics due to the lack of resistance to the acidity of food matrices, high temperature during food processing, and oxygen changes during storage also limit the applications of probiotics in food products. Therefore, encapsulation of probiotics could particularly protect the probiotics from degradation and inactivation, resulting in enhanced viability during the transition from consumption to digestion in the gut. Emulsion cross‐linking, complex coacervation, microcapsules, spray drying, layer‐by‐layer self‐assembly, electrospinning, hydrogel, and other methods are used to encapsulate probiotics. Herein, this review mainly highlights the gut health functions and encapsulation techniques of probiotics, followed by the current challenges and future development prospects.

show abstract